Education:
07/2002 – 06/2006 Cook County Hospital Obstetrics and Gynecology Internship and Residency Program Chicago, IL
08/1997 – 05/2002 DO, Nova Southeastern University College of Osteopathic Medicine Ft. Lauderdale, FL
08/1994 – 05/1997 MS, Barry University, Major: Biomedical Sciences Miami, FL
08/1989 – 05/1994 BS, Florida International University, Major: Biological Sciences Miami, FL
BOARD CERTIFICATION S AND LICENSURE/TRAINING:
- Board Certified in Obstetrics and Gynecology, since 10/2011
- Permanent Florida License # OS 10504 2008 to Present
- Florida Board of Health Level 3 Office Surgery License
- Permanent Illinois License # 036115407
- DEA # BG978xxxx
- Basic Cardiac Life Support (BCLS)
- Advanced Cardiac Life Support (ACLS)
- Neonatal Resuscitation Provider (NRP)
PROFESSIONAL EXPERIENCE:
2016 – Present Doral Medical Research, LLC
2015 – 2016 Universal Clinical Research Associates
2009 to Present Dr. Victoria Garcia & Associates, LLC
AWARDS:
Chancellor’s Medicine Scholarship
Full Medicine Scholarship Nova Southeastern University
TEACHING APPOINTMENTS:
12/2015 Associate Clinical Professor FIU OB/GYN Residents
01/2015 Associate Clinical Professor Medical Student NSU-COM OB/GYN
PROFESSIONAL AFFILIATIONS:
Fellow, American College of Osteopathic Obstetrics and Gynecology
Junior Fellow, American College of Obstetrics and Gynecology
Member, American Osteopathic Association
Member, American Medical Association
Member, Illinois Osteopathic Medical Society
Member, American Urogynecology Society
Member, Florida Medical Association
Member, Florida Obstetrics and Gynecology Society
Member, Florida Osteopathic Medical Association
HOSPITALS:
Kendall Regional Medical Center
Palmetto General Hospital
RESEARCH CERTIFICATIONS/TRAININGS:
NIH Certification
GCP Certification (CITI Program)
CLINICAL RESEARCH:
Principal Investigator
Merck Sharp & Dohme Corp: A Phase 2a, Proof of Concept, Randomized, Double-blind, Placebo-controlled Clinical Trial, to Evaluate the Efficacy and Safety of MK-7264 in Women with Moderate to Severe Endometriosis-related Pain. 2018
Janssen Pharmaceuticals: A Randomized, Double-blind, Placebo-controlled, First-in-Human, Phase 1/2a/2b Study to Evaluate Safety, Reactogenicity, Regimen Selection, Immunogenicity and Efficacy of Monovalent HPV16 and HPV18 Ad26-vectored Vaccine Components and an MVA-vectored HPV16/18 Vaccine Component in Otherwise Healthy Women with Persistent HPV16 or 18 Infection of the Cervix. 2018
Bayer Pharmaceuticals: A randomized, parallel-group, double-blind and open-label, placebo-controlled, multicenter study to assess the efficacy and safety of XXXXXX in subjects with uterine fibroids. 2018
Bayer Pharmaceuticals: A randomized, parallel-group, double-blind and open-label, placebo-controlled, multicenter study to assess the efficacy and safety of XXXXX in subjects with uterine fibroids. 2018
Myovant Sciences: An international Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate XXXXX Co-Administered with ad without Low-Dose Estradiol and Norethindrone Acetate in Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids. 2017
Bayer Pharmaceuticals: An open-label, parallel-group, randomized, multicenter study to assess the safety and efficacy of XXXXX in subjects with uterine fibroids versus standard of care. 2017 NCT03194646
AbbVie: Phase III Fibroid Study; Menstrual flow research to XXX medication versus Placebo. 01/2016
AbbVie: Phase III Endometriosis Study to test the safe ty and efficacy of XXXX administered orally. 05/2013-05/2015(
Phase III Anemia Association with Uterine Fibroids 06/2012 to 01/2013
Phase III Evaluation of Safety, Pharmacokinetics, and Efficacy of XXXX Administered Vaginally on Woman with Uterine Fibroids. 01/2012 to 01/2013
Sub-Investigator
A Multicenter, Randomized, Double- Blind, Placebo-Controlled, Phase III Study to Evaluate Cardiovascular Outcomes of XXX, SO mg in addition to Standard of care in Subjects with type 2 Diabetes and with Cardiovascular Disease or Multiple Risk Factors for Cardiovascular events
Phase III, Randomized, Double-Blind, Active-Controlled, Parallel -Group Study of the comparative Efficacy and Safety of XXX in subjects with Acute Otitis Externa
Phase IV Global Registry on Long-term Oral Anti-Thrombotic treatment in patients with Atrial Fibrillation Phase II and Ill
A Study in Japan and Ex-Japan to Characterized the Pharmacokinetic and Pharmacodynamic Response to Oteronel (XXX-700) in Chemotherapy Naïve patients with Castration -Resistant Prostate Cancer
An Open Label, Randomized, Comparison of the Immunogenicity and Safety of Human Insulin Basal Bolus Regimen (XXXX 70 -30) with the Sponsor Yeast based Human Insulin Basal Bolus Regimens, marketed in the United States (XXXX 70/30) in Type I Diabetes
An open Label study to evaluate the safety. Tolerability and Pharmacokinetics of XXXX in Combination with other anti-retroviral (ARVs) in antiretroviral treatment-experienced HIV-1 infected subjects,2012 – Cardiovascular Outcomes Study to evaluate the potential of XXXX to reduce cardiovascular risk in patients with a recent acute coronary syndrome (ACS) event and type 2 diabetes mellitus (T2DM)
An Open Label, 52-week study to assess the Long-Term Safety of XXXX in Opioid-Induced Constipation (OIC) in Patients with Cancer-Related Pain Senior Research Project: Mode of Delivery in HIV infected Patients at Cook County Hospital
X Biotech USA, Inc: A Phase II, Open Label, Dose Escalation Study of XXXXX in Patients with Moderate to Severe Hidradenitis Suppurativa
X Biotech USA Inc: A Phase II, Open Label, Dose Escalation Study of XXXXX in Patients with Moderate to Severe Atopic Dermatitis
Yiling Pharmaceutical, Inc: A Multi-Center, Randomized, Double-Blind, And Placebo-Controlled Phase II Clinical Study to Investigate the Safety and Efficacy Of Two Doses Of KT07 Compared To Placebo In Subjects with Acute Uncomplicated Influenza.
Master’s Thesis: The Role of Protein Kinas C Levels in Spontaneously Hypersensitive Rat
PI credentials: Elaris UF1 and UF2. “Elagolix therapy for Heavy Menstrual bleeding in Women with Uterine Fibroids” New England Journal of Medicine.
VOLUNTEER:
05/2009- Present Manoguayo Dominican Republic
01/2007-01/2009 Family Health Partnership Clinic – Volunteer Clinic Gynecology Services/ Surgeries to indigent patients in the community.
03/2002 Medical Mission to Delhi, India
06/2001 Medical Mission to the Dominican Republic
01/2000 DOCARE Medical Mission to Antigua, Guatemala
REFRENCES: Upon request